Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 300 of 1475 entries
View as:

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Phase: N/A Priority: Normal
NCT ID: NCT04908202 Org: User:
Start: 07/13/21 End: 06/10/27 Due: 06/10/28

Pan Tumor Rollover Study

Phase: N/A Priority: Normal
NCT ID: NCT03899155 Org: User:
Start: 08/09/19 End: 08/25/29 Due: 08/25/30

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT04965402 Org: User:
Start: 07/15/21 End: 02/07/22 Due: 02/07/23

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Phase: N/A Priority: Normal
NCT ID: NCT02658890 Org: User:
Start: 04/14/16 End: 10/26/21 Due: 10/26/22

Drug Interaction Statin

Phase: N/A Priority: Normal
NCT ID: NCT02089061 Org: User:
Start: 03/31/14 End: 05/31/14 Due: 05/31/15

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Phase: N/A Priority: Normal
NCT ID: NCT05633264 Org: User:
Start: 12/05/22 End: 05/31/25 Due: 05/31/26

A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition

Phase: N/A Priority: Normal
NCT ID: NCT00002300 Org: User:
Start: - End: - Due: -

Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins

Phase: N/A Priority: Normal
NCT ID: NCT01587365 Org: User:
Start: 05/31/12 End: 05/31/13 Due: 05/31/14

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01024231 Org: User:
Start: 12/14/09 End: 04/01/19 Due: 04/01/20

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Phase: N/A Priority: Normal
NCT ID: NCT02754154 Org: User:
Start: 12/31/14 End: 12/26/18 Due: 12/26/19

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT03400163 Org: User:
Start: 05/08/15 End: 06/19/17 Due: 06/19/18

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00084656 Org: User:
Start: 05/31/04 End: 10/31/09 Due: 10/31/10

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01389323 Org: User:
Start: 09/30/11 End: 01/31/14 Due: 01/31/15

Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT01990859 Org: User:
Start: 12/31/13 End: 02/28/15 Due: 02/28/16

Dose Ranging Study With LT, Monotherapy, PPAR

Phase: N/A Priority: Normal
NCT ID: NCT00240383 Org: User:
Start: 05/31/02 End: 06/30/06 Due: 06/30/07

Effect of BMS-914392 on Pharmacokinetics of Metoprolol

Phase: N/A Priority: Normal
NCT ID: NCT01211821 Org: User:
Start: 09/30/10 End: 11/30/10 Due: 11/30/11

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

Phase: N/A Priority: Normal
NCT ID: NCT02551861 Org: User:
Start: 12/31/15 End: 06/30/17 Due: 06/30/18

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Phase: N/A Priority: Normal
NCT ID: NCT01204762 Org: User:
Start: 11/30/10 End: 12/31/13 Due: 12/31/14

A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00067782 Org: User:
Start: 12/31/02 End: 03/31/05 Due: 03/31/06

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Phase: N/A Priority: Normal
NCT ID: NCT03521908 Org: User:
Start: 06/13/16 End: 11/23/18 Due: 11/23/19

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT02823574 Org: User:
Start: 11/08/16 End: 04/21/22 Due: 04/21/23

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Phase: N/A Priority: Normal
NCT ID: NCT03138499 Org: User:
Start: 06/26/17 End: 02/22/21 Due: 02/22/22

Expanded Access Program With Nivolumab to Treat Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02142218 Org: User:
Start: 06/30/14 End: 05/31/18 Due: 05/31/19

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00825955 Org: User:
Start: 02/17/09 End: 08/25/17 Due: 08/25/18

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03956953 Org: User:
Start: 04/04/19 End: 09/25/19 Due: 09/25/20